Published in Cancers (Basel) on March 24, 2011
Therapeutic targeting of Neu1 sialidase with oseltamivir phosphate (Tamiflu®) disables cancer cell survival in human pancreatic cancer with acquired chemoresistance. Onco Targets Ther (2014) 0.92
Targeted noninvasive imaging of EGFR-expressing orthotopic pancreatic cancer using multispectral optoacoustic tomography. Cancer Res (2014) 0.87
The involvement of insulin-like growth factor 2 binding protein 3 (IMP3) in pancreatic cancer cell migration, invasion, and adhesion. BMC Cancer (2015) 0.83
A novel NHE1-centered signaling cassette drives epidermal growth factor receptor-dependent pancreatic tumor metastasis and is a target for combination therapy. Neoplasia (2015) 0.83
Kaempferol Inhibits Pancreatic Cancer Cell Growth and Migration through the Blockade of EGFR-Related Pathway In Vitro. PLoS One (2016) 0.81
The Potential of panHER Inhibition in Cancer. Front Oncol (2015) 0.80
Biomarkers and Targeted Therapy in Pancreatic Cancer. Biomark Cancer (2016) 0.79
ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology. Cancers (Basel) (2017) 0.77
Neuraminidase-1: a novel therapeutic target in multistage tumorigenesis. Oncotarget (2016) 0.77
Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward. Int J Mol Sci (2017) 0.75
Transcriptional factor snail controls tumor neovascularization, growth and metastasis in mouse model of human ovarian carcinoma. Clin Transl Med (2014) 0.75
Connexin-43 channels are a pathway for discharging lactate from glycolytic pancreatic ductal adenocarcinoma cells. Oncogene (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 27.35
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med (2004) 13.34
Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med (2005) 13.01
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst (2005) 13.00
EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol (2006) 10.39
EGFR antagonists in cancer treatment. N Engl J Med (2008) 9.68
The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J (2000) 9.51
Epidermal growth factor receptor (EGFR) signaling in cancer. Gene (2005) 6.04
The EGF receptor family as targets for cancer therapy. Oncogene (2000) 5.44
Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol (2003) 5.22
EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol (2005) 5.07
Epidermal growth factor receptor targeting in cancer. Semin Oncol (2006) 3.84
Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol (2011) 3.52
Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg (2001) 2.94
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res (2005) 2.46
Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res (1993) 2.15
The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas (2004) 2.05
Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res (2006) 1.75
Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. Int J Mol Med (2003) 1.61
Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J Pathol (1991) 1.58
Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique. Dig Surg (2006) 1.44
Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer (2007) 1.42
Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res (2003) 1.37
Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res (2000) 1.35
Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer. Proc Natl Acad Sci U S A (1986) 1.33
Mechanisms of egfr gene transcription modulation: relationship to cancer risk and therapy response. Clin Cancer Res (2006) 1.32
The epidermal growth factor. Cell Biol Int (1995) 1.25
Relevance of biologic markers in colorectal carcinoma: a comparative study of a broad panel. Cancer (2002) 1.22
Epidermal growth factor receptor R497K polymorphism is a favorable prognostic factor for patients with colorectal carcinoma. Clin Cancer Res (2007) 1.10
Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer. Clin Colorectal Cancer (2005) 1.09
Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. Surgery (2007) 1.07
Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer. Anticancer Res (1999) 1.02
EGFR R497K polymorphism is a favorable prognostic factor for advanced lung cancer. J Cancer Res Clin Oncol (2008) 1.01
Molecular aspects of pancreatic cancer and future perspectives. Dig Surg (1999) 1.00
Genetic analysis of hyperproduction of epidermal growth factor receptors in human epidermoid carcinoma A431 cells. Somat Cell Mol Genet (1984) 0.99
Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Arch (2006) 0.99
Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response. Ann Surg Oncol (2007) 0.98
Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients. Ann Oncol (2005) 0.97
Two chromosome 7 dinucleotide repeat polymorphisms at gene loci epidermal growth factor receptor (EGFR) and pro alpha 2 (I) collagen (COL1A2). Hum Mol Genet (1992) 0.96
Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer. Anticancer Res (1998) 0.96
Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Biochim Biophys Acta (2006) 0.94
Modulation of EGFR gene transcription by secondary structures, a polymorphic repetitive sequence and mutations--a link between genetics and epigenetics. Histol Histopathol (2000) 0.92
An effect of K-ras gene mutation on epidermal growth factor receptor signal transduction in PANC-1 pancreatic carcinoma cells. Int J Cancer (1996) 0.89
Molecular diagnosis of pancreatic cancer. Hepatogastroenterology (2001) 0.88
Exon 19 of EGFR mutation in relation to the CA-repeat polymorphism in intron 1. Cancer Sci (2008) 0.86
Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review. Oncologist (2006) 0.84
Frequent mutations of the CA simple sequence repeat in intron 1 of EGFR in mismatch repair-deficient colorectal cancers. World J Gastroenterol (2008) 0.84
Effect of reduced EGFR function on the radiosensitivity and proliferative capacity of mouse jejunal crypt clonogens. Radiother Oncol (2004) 0.84
Immunohistochemical expression of transforming growth factor alpha and epidermal growth factor receptor in pancreatic endocrine tumors. Hum Pathol (2001) 0.81
Epidermal growth factor receptor (EGFR) intron 1 polymorphism and clinical outcome in pancreatic adenocarcinoma. Am J Surg (2010) 0.80
Epidermal growth factor receptor-related protein inhibits cell growth and induces apoptosis of BxPC3 pancreatic cancer cells. Cancer Res (2005) 0.79
Registration of resected lung cancer in Niigata Prefecture. Jpn J Thorac Cardiovasc Surg (2004) 0.77
Determinant-based classification of acute pancreatitis severity: an international multidisciplinary consultation. Ann Surg (2012) 5.55
Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet (2009) 4.61
Open pancreatic necrosectomy in the multidisciplinary management of postinflammatory necrosis. Ann Surg (2010) 2.97
Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome. Am J Hum Genet (2007) 2.73
Mesh fixation at laparoscopic inguinal hernia repair: a meta-analysis comparing tissue glue and tack fixation. World J Surg (2014) 2.66
EGFR and KRAS mutational analysis and their correlation to survival in pancreatic and periampullary cancer. Pancreas (2012) 1.65
Assessing individual breast cancer risk within the U.K. National Health Service Breast Screening Program: a new paradigm for cancer prevention. Cancer Prev Res (Phila) (2012) 1.59
European survey of surgical strategies for the management of severe acute pancreatitis. Am J Gastroenterol (2004) 1.56
The liver-first approach to the management of colorectal cancer with synchronous hepatic metastases: a systematic review. JAMA Surg (2013) 1.52
The end of cryotherapy for the treatment of nonresectable hepatic tumors? Ann Surg Oncol (2005) 1.40
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. Cancer Cell (2011) 1.40
Radiofrequency ablation of liver tumours: systematic review. Lancet Oncol (2004) 1.38
Perrault syndrome is caused by recessive mutations in CLPP, encoding a mitochondrial ATP-dependent chambered protease. Am J Hum Genet (2013) 1.37
Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics (2010) 1.35
Systematic appraisal of the role of metallic endobiliary stents in the treatment of benign bile duct stricture. Ann Surg (2005) 1.30
Mutations in HPSE2 cause urofacial syndrome. Am J Hum Genet (2010) 1.24
Systematic appraisal of the management of the major vascular complications of pancreatitis. Am J Surg (2005) 1.22
Identification of a mutation in the ubiquitin-fold modifier 1-specific peptidase 2 gene, UFSP2, in an extended South African family with Beukes hip dysplasia. S Afr Med J (2015) 1.22
The mutational spectrum of brachydactyly type C. Am J Med Genet (2002) 1.22
Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat (2010) 1.18
Role of tumor necrosis factor-alpha in acute pancreatitis: from biological basis to clinical evidence. Shock (2007) 1.13
Current status of tumor M2 pyruvate kinase (tumor M2-PK) as a biomarker of gastrointestinal malignancy. Ann Surg Oncol (2007) 1.11
Valuing pharmacogenetic testing services: a comparison of patients' and health care professionals' preferences. Value Health (2011) 1.10
Markers of angiogenesis in synchronous and in metachronous colorectal hepatic metastases. Ann Surg (2015) 1.08
Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. Nat Genet (2013) 1.05
Understanding the colonic complications of pancreatitis. Pancreatology (2008) 1.04
Cholecystitis after cholecystectomy. J R Soc Med (2002) 1.00
Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients. Breast Cancer Res Treat (2012) 1.00
Radiofrequency ablation for locally advanced cancer of the pancreas. JOP (2006) 0.99
Extended spectrum of human glucose-6-phosphatase catalytic subunit 3 deficiency: novel genotypes and phenotypic variability in severe congenital neutropenia. J Pediatr (2011) 0.99
Evidence for a central role for selective mesenteric angiography in the management of the major vascular complications of pancreatitis. Am J Surg (2003) 0.98
LRIG2 mutations cause urofacial syndrome. Am J Hum Genet (2013) 0.97
Further delineation of the phenotype of severe congenital neutropenia type 4 due to mutations in G6PC3. Eur J Hum Genet (2010) 0.96
Quality of life assessment in patients with chronic pancreatitis receiving antioxidant therapy. World J Gastroenterol (2010) 0.95
Development and validation of an experimental model for the assessment of radiofrequency ablation of pancreatic parenchyma. Pancreas (2005) 0.94
Fine-mapping CASP8 risk variants in breast cancer. Cancer Epidemiol Biomarkers Prev (2011) 0.94
Effects of thalidomide in a mouse model of cerulein-induced acute pancreatitis. Shock (2008) 0.93
Variability of bone marrow morphology in G6PC3 mutations: is there a genotype-phenotype correlation or age-dependent relationship? Am J Hematol (2011) 0.93
Pharmacogenetic testing in the United Kingdom genetics and immunogenetics laboratories. Genet Test Mol Biomarkers (2010) 0.93
UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan. Pharmacogenomics (2009) 0.92
CTLA4/ICOS gene variants and haplotypes are associated with rheumatoid arthritis and primary biliary cirrhosis in the Canadian population. Arthritis Rheum (2009) 0.92
Perrault syndrome: further evidence for genetic heterogeneity. J Neurol (2011) 0.91
TNF-alpha as a therapeutic target in acute pancreatitis--lessons from experimental models. ScientificWorldJournal (2007) 0.90
Breast cancer susceptibility variants alter risks in familial disease. J Med Genet (2009) 0.90
Diagnostic and prognostic value of plasma tumor M2 pyruvate kinase in periampullary cancer: evidence for a novel biological marker of adverse prognosis. Pancreas (2007) 0.89
Identification and characterization of an inborn error of metabolism caused by dihydrofolate reductase deficiency. Am J Hum Genet (2011) 0.89
Centralisation of upper gastrointestinal cancer surgery. Ann R Coll Surg Engl (2007) 0.89
Experimental and clinical evidence for modification of hepatic ischaemia-reperfusion injury by N-acetylcysteine during major liver surgery. HPB (Oxford) (2011) 0.89
Etanercept attenuates the development of cerulein-induced acute pancreatitis in mice: a comparison with TNF-alpha genetic deletion. Shock (2007) 0.88
Muscarinic Acetylcholine Receptor M3 Mutation Causes Urinary Bladder Disease and a Prune-Belly-like Syndrome. Am J Hum Genet (2011) 0.88
Mutations in the G6PC3 gene cause Dursun syndrome. Am J Med Genet A (2010) 0.88
Nutritional and anthropometric assessment of the scope for dietary optimization during staging prior to pancreaticoduodenectomy. JOP (2008) 0.87
Germline SMARCE1 mutations predispose to both spinal and cranial clear cell meningiomas. J Pathol (2014) 0.87
A clinical and molecular review of ubiquitous glucose-6-phosphatase deficiency caused by G6PC3 mutations. Orphanet J Rare Dis (2013) 0.87
Replication and meta-analysis of 13,000 cases defines the risk for interleukin-23 receptor and autophagy-related 16-like 1 variants in Crohn's disease. Can J Gastroenterol (2010) 0.87
Intronic splicing mutations in PTCH1 cause Gorlin syndrome. Fam Cancer (2014) 0.86
Microfluidic platform for single nucleotide polymorphism genotyping of the thiopurine S-methyltransferase gene to evaluate risk for adverse drug events. J Mol Diagn (2007) 0.85
Expanding the clinical spectrum of SLC29A3 gene defects. Eur J Med Genet (2010) 0.85
Spontaneous ovarian hyperstimulation syndrome: case report, pathophysiological classification and diagnostic algorithm. Eur J Obstet Gynecol Reprod Biol (2013) 0.84
Pernicious anemia - genetic insights. Autoimmun Rev (2011) 0.84
Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations. Eur J Hum Genet (2012) 0.84
Urofacial syndrome: a genetic and congenital disease of aberrant urinary bladder innervation. Pediatr Nephrol (2013) 0.84
Sequential endovascular repair and pancreaticoduodenectomy for abdominal aortic aneurysm copresenting with periampullary cancer. Ann Vasc Surg (2006) 0.83
Early diagnosis and treatment of cobalamin deficiency of infancy owing to occult maternal pernicious anemia. J Pediatr Hematol Oncol (2010) 0.83
A common Asn680Ser polymorphism in the follicle-stimulating hormone receptor gene is not associated with ovarian response to gonadotropin stimulation in patients undergoing in vitro fertilization. Fertil Steril (2012) 0.83
Developing national guidance on genetic testing for breast cancer predisposition: the role of economic evidence? Genet Test Mol Biomarkers (2012) 0.83
Inhibition of tyrosine-kinase-mediated cellular signaling by tyrphostins AG 126 and AG556 modulates murine experimental acute pancreatitis. Surgery (2005) 0.82
G6PC3 mutations cause non-syndromic severe congenital neutropenia. Mol Genet Metab (2012) 0.82
PCOS and peripheral AMH levels in relation to FSH receptor gene single nucleotide polymorphisms. Gynecol Endocrinol (2012) 0.82
Follicle-stimulating hormone receptor gene polymorphisms are not associated with ovarian reserve markers. Fertil Steril (2012) 0.82
High sensitivity for BRCA1/2 mutations in breast/ovarian kindreds: are there still other breast/ovary genes to be discovered? Breast Cancer Res Treat (2012) 0.82
Current status of laparoscopic biliary bypass in the management of non-resectable peri-ampullary cancer. Pancreatology (2005) 0.82
Drotrecogin alfa (recombinant human activated protein C) in severe acute pancreatitis. Crit Care (2005) 0.82
Pharmacogenetics of aromatase inhibitors. Pharmacogenomics (2012) 0.81
Intravenous selenium modulates L-arginine-induced experimental acute pancreatitis. JOP (2005) 0.81
Increased rate of phenocopies in all age groups in BRCA1/BRCA2 mutation kindred, but increased prospective breast cancer risk is confined to BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2013) 0.81
The performance of organ dysfunction scores for the early prediction and management of severity in acute pancreatitis: an exploratory phase diagnostic study. Pancreas (2010) 0.80
Recombinant human activated protein C (Xigris) attenuates murine cerulein-induced acute pancreatitis via regulation of nuclear factor κB and apoptotic pathways. Pancreas (2012) 0.80
Avoidance of CYP2D6 inhibitors in patients receiving tamoxifen. J Clin Oncol (2010) 0.80
Green tea polyphenols ameliorate pancreatic injury in cerulein-induced murine acute pancreatitis. Pancreas (2009) 0.80
Diagnostic Mutation Profiling and Validation of Non-Small-Cell Lung Cancer Small Biopsy Samples using a High Throughput Platform. J Thorac Oncol (2015) 0.80
Insulin protects pancreatic acinar cells from cytosolic calcium overload and inhibition of plasma membrane calcium pump. J Biol Chem (2011) 0.80
Pharmacogenetics and pharmacogenomics: a clinical reality. Ann Clin Biochem (2011) 0.80
Recombinant human activated protein C as a disease modifier in severe acute pancreatitis: systematic review of current evidence. Pancreatology (2012) 0.79
Evaluation of the Manchester classification system for chronic pancreatitis. JOP (2006) 0.78
The SPINK1 N34S variant is associated with acute pancreatitis. Eur J Gastroenterol Hepatol (2009) 0.78
Lack of caveolin-1 (P132L) somatic mutations in breast cancer. Breast Cancer Res Treat (2012) 0.78
Genetics of human congenital urinary bladder disease. Pediatr Nephrol (2013) 0.78
Inflammatory bowel disease in the South Asian population of Northwest England. Am J Gastroenterol (2008) 0.78
Contemporary management of perihilar cholangiocarcinoma in a nontransplant hepatopancreatobiliary center. Eur J Gastroenterol Hepatol (2013) 0.78
General surgery in patients with a bleeding diathesis: how we do it. World J Surg (2011) 0.78
Cytokine profiles in patients receiving antioxidant therapy within the ANTICIPATE trial. World J Gastroenterol (2013) 0.77
Poly(adenylic acid) complementary DNA real-time polymerase chain reaction in pancreatic ductal juice in patients undergoing pancreaticoduodenectomy. Pancreas (2010) 0.77
FSH receptor genotype does not predict metaphase-II oocyte output or fertilization rates in ICSI patients. Reprod Biomed Online (2013) 0.77
Glycolytic ATP fuels the plasma membrane calcium pump critical for pancreatic cancer cell survival. J Biol Chem (2013) 0.77